StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note released on Thursday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
Shares of TTNP stock opened at $3.85 on Thursday. Titan Pharmaceuticals has a fifty-two week low of $3.63 and a fifty-two week high of $14.80. The company has a 50 day moving average price of $5.54 and a 200 day moving average price of $6.02.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- Golden Cross Stocks: Pattern, Examples and Charts
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is a SEC Filing?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- 5 discounted opportunities for dividend growth investors
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
